News

• VG901 is the first-in-class and only clinical-stage therapy designed to deliver the functional CNGA1 gene intravitreally (IVT) to target retinal photoreceptor cells in patients with retinitis pigmentosa • FDA Rare Pediatric Disease Designation qualifies ViGeneron for potential eligibility for a Priority Review Voucher (PRV) upon marketing approval • The independent Data Safety Monitoring Board […]

• VG801 is the first FDA IND clearance for novel mRNA trans-splicing gene therapy, delivering the full-length functional ABCA4 gene to target the genetic root cause of retinal dystrophies associated with ABCA4 mutations • VG801 IND clearance expands ViGeneron’s clinical-stage pipeline to two programs, utilizing its novel gene therapy delivery technology platforms vgAAV capsid and […]

VG901 is the first and only clinical-stage therapy designed to deliver a functional CNGA1 gene to retinal photoceptor target cells in retinitis pigmentosa patients VG901, using ViGeneron’s proprietary next-generation technology platform vgAAV, is administered intravitreally (IVT), offering enhanced ease of delivery, broader vector distribution, and mitigating the risk of retinal damage linked with subretinal administration […]

REVeRT, a dual vector approach based on mRNA trans-splicing, enables delivery of genes larger than the usual AAV packaging size in various tissues Potential to address prevalent inherited diseases caused by larger genes such as Stargardt disease Delivery of CRISPR modules allows bi-directional modulation of multiple genes   Munich, Germany, October 25, 2023 –– ViGeneron […]

Munich, Germany, August 22, 2023 –– ViGeneron GmbH (ViGeneron), a next-generation gene therapy company, today announced that the European Medicines Agency (EMA) has approved the Clinical Trial Application (CTA) for VG901, a potentially transformative gene therapy to treat CNGA1-associated Retinitis Pigmentosa (RP), an ocular disorder currently lacking approved therapies. VG901 uses vgAAV, ViGeneron’s proprietary adeno-associated […]

Munich, Germany, June 30, 2023 –– ViGeneron GmbH, a next-generation gene therapy company, announced the appointment of Dr. Markus Kalousek as Chief Business & Strategy Officer (CBO) effective July 1st, 2023, to advance the next stage of corporate development. With more than 25 years of experience in the international biopharmaceutical sector, mainly in large corporations, […]

First gene therapy program targeting CNGA1 mutation in Retinitis Pigmentosa (RP) Novel vgAAV vector efficiently and safely delivers human CNGA1 gene via intravitreal injection in RP disease model ViGeneron to advance its VG901 program for RP through clinical development Munich, Germany, May 12, 2023 –– ViGeneron GmbH, a next-generation gene therapy company, announced today that […]

Efficient transfer of larger gene via ViGeneron’s proprietary technology platforms REVeRT and vgAAV ViGeneron advances its preclinical programs for Stargardt disease and Retinitis Pigmentosa into IND-enabling activities and clinical stage development Munich, Germany, October 11, 2022 –– ViGeneron GmbH, a next-generation gene therapy company, today announced the presentation of preclinical data on its program VG801 […]

ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop a novel gene therapy for prevalent eye diseases • The companies agree a follow-on collaboration to evaluate ViGeneron’s adeno-associated virus vectors (vgAAVs) for delivering Daiichi Sankyo’s novel therapeutic protein to treat prevalent eye diseases Munich, Germany, April 26, 2022 –– ViGeneron GmbH, a next-generation gene therapy […]

• Regeneron receives access to ViGeneron’s vgAAV capsids for one inherited retinal disease target and an option for an exclusive license to develop and commercialize the gene therapy product • ViGeneron is eligible to receive upfront payment, research funding, option exercise fee, development and commercial milestone payments, plus royalties on net sales • The collaboration […]

The companies will evaluate ViGeneron’s proprietary, intravitreally injected vgAAV vectors for delivering a novel therapeutic protein to develop a gene therapy treatment for a highly prevalent eye disease

ViGeneron has announced a global collaboration and licensing agreement with Biogen Inc. to develop and commercialize gene therapy products based on adeno-associated virus (AAV) vectors to treat inherited eye diseases. The companies will use ViGeneron’s proprietary vgAAV, novel engineered AAV capsids, to efficiently transduce retinal cells via intravitreal injections.

ViGeneron has announced a strategic partnership with WuXi Advanced Therapies Inc., a leading Contract, Testing, Development and Manufacturing Organization to accelerate production for the clinical development of VG901, a next-generation ophthalmic gene therapy program.

ViGeneron GmbH, a gene therapy company, announced the closing of its series A financing round led by WuXi AppTec and Sequoia Capital China. The proceeds will enable ViGeneron to accelerate its proprietary viral vector-based gene therapy platforms and drive product development in its two lead ophthalmic gene therapy programs. Funds will advance development of ViGeneron’s […]